Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)

• Status: Enrolling by invitation
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The actual evidence is solid about the use of de SGLT2-inhibitors in wide spectrum of cardiorenal targets, which has been shown in a great amount of randomized clinical trials compared with placebo. At present it must be taken into account as first line treatment in patients with DM2, even their security profile has allowed the use in patients without diagnosis of DM2, since they have be shown a beneficial cardioprotect effects. Most studies support they use in patients with high cardiovascular risk, nevertheless, their use in patients with recent diagnosis of ischemic hearth disease its limited, being the latter entity the most frequent etiology found in patients who develop chronic hearth failure either as part of heart attack or unstable angina.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Mexicano del Seguro Social
• Collaborators: Gabriel Fernández Yáñez; Germán Ramón Bautista López; Luis Jonathan González; Rodolfo Guardado Mendoza
• Treatments: 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; Dapagliflozin

Criteria

Inclusion Criteria:

• Male and female IMSS eligible patients over 18 years of age

• Meet the criteria of the fourth definition of ST-segment elevation myocardial infarction

• Known with diabetes mellitus 2 or newly diagnosed diabetes according to ADA criteria

Exclusion Criteria:

• Patients diagnosed with Type 1 Diabetes Mellitus

• Patients on chronic replacement therapy for renal function through peritoneal dialysis or hemodialysis

• Patients who have recently undergone immunosuppressive therapy

• Patients with a history of recurrent urinary tract infection

• Patients known to be allergic to SGLT-2 inhibitors

• Patients presenting as sudden aborted death

• Patients who after percutaneous coronary intervention require orotracheal intubation